Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. for potential securities fraud related to delays and a secondary complete response letter from the FDA for its generic teriparatide ANDA, AMP-015.
February 19, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation for potential securities fraud due to FDA's secondary CRL for its generic teriparatide ANDA, AMP-015, which may impact investor confidence.
The investigation into potential securities fraud and the FDA's secondary CRL for AMP-015 are significant negative factors that could erode investor confidence and lead to a short-term decline in Amphastar's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100